Short Interest in Exscientia plc (NASDAQ:EXAI) Grows By 15.7%

Exscientia plc (NASDAQ:EXAI - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling 3,690,000 shares, a growth of 15.7% from the July 31st total of 3,190,000 shares. Approximately 3.5% of the shares of the stock are sold short. Based on an average trading volume of 593,200 shares, the days-to-cover ratio is presently 6.2 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its position in shares of Exscientia by 112.1% in the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company's stock valued at $25,000 after buying an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Exscientia by 76.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,274 shares of the company's stock worth $53,000 after acquiring an additional 4,029 shares during the period. Vanguard Personalized Indexing Management LLC bought a new stake in Exscientia in the second quarter valued at approximately $54,000. Walled Lake Planning & Wealth Management LLC acquired a new stake in Exscientia during the 4th quarter valued at approximately $64,000. Finally, Federated Hermes Inc. bought a new position in Exscientia during the 2nd quarter worth approximately $115,000. Institutional investors and hedge funds own 41.58% of the company's stock.

Wall Street Analyst Weigh In

EXAI has been the subject of several recent analyst reports. TD Cowen restated a "hold" rating on shares of Exscientia in a research note on Friday, August 9th. Barclays reissued an "equal weight" rating and set a $5.00 price target on shares of Exscientia in a report on Tuesday, August 13th.

Exscientia Price Performance

EXAI stock traded down $0.10 during trading on Monday, reaching $5.56. 752,700 shares of the company were exchanged, compared to its average volume of 637,763. Exscientia has a twelve month low of $3.80 and a twelve month high of $7.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The company has a market capitalization of $672.13 million, a price-to-earnings ratio of -4.24 and a beta of 0.85. The company has a 50-day moving average of $5.33 and a two-hundred day moving average of $5.35.

Exscientia (NASDAQ:EXAI - Get Free Report) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.05). Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. The firm had revenue of $5.60 million during the quarter. As a group, equities analysts predict that Exscientia will post -1.25 earnings per share for the current fiscal year.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.